NicOx S.A., a biopharmaceutical company, engages in the development and commercialization of nitric oxide (NO)-donating drugs primarily for inflammation and cardio-metabolic diseases. The company's primary products candidates include Naproxcinod, a Phase III product candidate for the treatment of osteoarthritis; and NCX 6560, a NO-donating compound for the treatment of cardiovascular diseases, which is in phase I clinical trials. Its product portfolio comprise PF-03187207 for the treatment of glaucoma, TPI 1020 for the treatment of respiratory disorders, and NCX 1510 for allergic rhinitis, which are in Phase II clinical trials; and NO-donating antihypertensives, which is in phase I clinical trials for the treatment of hypertension. The company's product pipeline also include NCX 1047, which is in preclinical stage of development for treating a range of skin disorders, such as atopic dermatitis, psoriasis, and seborrheic dermatitis; and NO-donors for diabetic retinopathy, cardiometabolic, inflammation, and pain. It has research and co-development agreement with Orexo AB to identify and develop compounds for the treatment of airway diseases; license and development agreement with TOPIGEN Pharmaceuticals Inc. The company also has agreements with Grupo Ferrer Internacional SA for the research, development, and marketing of NO-donating anti-inflammatory drugs for the treatment of dermatological diseases; Pfizer Inc to identify nitric oxide-donating compounds for diabetic retinopathy; and Merck & Co., Inc. for the development of new antihypertensive drugs using NicOx' nitric oxide-donating technology. NicOx S.A. was founded in 1996 and is headquartered in Sophia Antipolis, France.

Show more
TypePublic
HQValbonne, FR
Size (employees)134 (est)
Websitenicox.com
NicOx is headquartered in Valbonne, FR
Report incorrect company information

Viewing summary data as a guest

Sign up for free to see all data

Key People/Management at NicOx

Michele Garufi

Michele Garufi

Co-Founder, Chairman and Chief Executive Officer
Michael BERGAMINI

Michael BERGAMINI

Executive-Vice President, Chief Scientific Officer
Sandrine GESTIN

Sandrine GESTIN

Vice President, Finance
Tomas Navratil

Tomas Navratil

Executive-Vice President, Head of Development
Emmanuelle Pierry

Emmanuelle Pierry

Senior Director of Legal Affairs
Gavin SPENCER

Gavin SPENCER

Executive Vice-President, Chief Business Officer
Show more

NicOx Office Locations

NicOx has offices in Fort Worth, Valbonne and Bresso
Bresso, IT
21 Via Ludovico Ariosto
Fort Worth, US
1292 777 Main St
Show all (3)
Report incorrect company information

NicOx Blogs

Nicox Announces Intention to Conduct a Registered Offering on NASDAQ in the United States

Sophia Antipolis, France Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmic company, announced today that it has previously confidentially submitted a draft registration statement on Form F-1 to the U.S. Securities and Exchange Commission relating to the proposed offering of A…
Show more

NicOx Company Life and Culture

Report incorrect company information